T1	PROC 273 286	retratamiento
#1	AnnotatorNotes T1	C0376495; Retreatments; Therapeutic or Preventive Procedure
T2	PROC 17 45	tratamiento de mantenimiento
#2	AnnotatorNotes T2	C0677908; Maintenance therapy; Therapeutic or Preventive Procedure
T3	DISO 67 99	enfermedad de Crohn fistulizante
#3	AnnotatorNotes T3	C3888864; Fistulising Crohn's disease; Disease or Syndrome
T4	CHEM 115 125	infliximab
#4	AnnotatorNotes T4	C0666743; infliximab; Amino Acid, Peptide, or Protein · Pharmacologic Substance · Immunologic Factor
T5	PROC 158 169	tratamiento
#5	AnnotatorNotes T5	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T6	PROC 359 370	se trataron
#6	AnnotatorNotes T6	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T7	DISO 190 224	enfermedad de Crohn (EC) fistulosa
#7	AnnotatorNotes T7	C3888864; Fistulising Crohn's disease; Disease or Syndrome
T8	PROC 479 491	tratamientos
#8	AnnotatorNotes T8	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T9	PROC 293 321	tratamiento de mantenimiento
#9	AnnotatorNotes T9	C0677908; Maintenance therapy; Therapeutic or Preventive Procedure
T10	CHEM 375 385	infliximab
#10	AnnotatorNotes T10	C0666743; infliximab; Amino Acid, Peptide, or Protein · Pharmacologic Substance · Immunologic Factor
T11	PROC 775 788	retratamiento
#11	AnnotatorNotes T11	C0376495; Retreatments; Therapeutic or Preventive Procedure
T12	DISO 428 440	EC fistulosa
#12	AnnotatorNotes T12	C3509259; crohn's disease with fistula; Disease or Syndrome
T13	PROC 537 548	tratamiento
#13	AnnotatorNotes T13	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T14	PROC 910 935	programa de mantenimiento
#14	AnnotatorNotes T14	C0677908; Maintenance therapy; Therapeutic or Preventive Procedure
T15	PROC 862 886	terapia de retratamiento
#15	AnnotatorNotes T15	C0376495; Retreatments; Therapeutic or Preventive Procedure
T16	PROC 1190 1203	retratamiento
#16	AnnotatorNotes T16	C0376495; Retreatments; Therapeutic or Preventive Procedure
T17	PROC 1061 1072	tratamiento
#17	AnnotatorNotes T17	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T18	PROC 1772 1785	retratamiento
#18	AnnotatorNotes T18	C0376495; Retreatments; Therapeutic or Preventive Procedure
T19	PROC 1360 1388	tratamiento de mantenimiento
#19	AnnotatorNotes T19	C0677908; Maintenance therapy; Therapeutic or Preventive Procedure
T20	PROC 1508 1519	tratamiento
#20	AnnotatorNotes T20	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T21	DISO 1557 1573	efectos adversos
#21	AnnotatorNotes T21	C0041755; Adverse reaction to drug; Pathologic Function | C0559546; Adverse reactions; Pathologic Function | C0879626; Adverse effects; Pathologic Function
T22	PROC 1673 1684	tratamiento
#22	AnnotatorNotes T22	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T23	CHEM 1749 1759	infliximab
#23	AnnotatorNotes T23	C0666743; infliximab; Amino Acid, Peptide, or Protein · Pharmacologic Substance · Immunologic Factor
T24	PROC 1791 1819	tratamiento de mantenimiento
#24	AnnotatorNotes T24	C0677908; Maintenance therapy; Therapeutic or Preventive Procedure
T25	DISO 1887 1916	enfermedad de Crohn fistulosa
#25	AnnotatorNotes T25	C3888864; Fistulising Crohn's disease; Disease or Syndrome
T26	PROC 1624 1637	retratamiento
#26	AnnotatorNotes T26	C0376495; Retreatments; Therapeutic or Preventive Procedure
T27	CHEM 50 60	infliximab
#27	AnnotatorNotes T27	C0666743; infliximab; Amino Acid, Peptide, or Protein · Pharmacologic Substance · Immunologic Factor
T28	PROC 557 567	infusiones
#28	AnnotatorNotes T28	C0574032; Infusion procedures; Therapeutic or Preventive Procedure
T29	PROC 979 989	infusiones
#29	AnnotatorNotes T29	C0574032; Infusion procedures; Therapeutic or Preventive Procedure
T30	PROC 1730 1744	administración
#30	AnnotatorNotes T30	C1533734; Administration procedure; Therapeutic or Preventive Procedure
T31	PROC 1 14	Retratamiento
#31	AnnotatorNotes T31	C0376495; Retreatments; Therapeutic or Preventive Procedure
T32	Date 170 183	a corto plazo
T33	Date 322 335	a largo plazo
T34	LIVB 338 347	Pacientes
#32	AnnotatorNotes T34	C0030705; Patients; Patient or Disabled Group
T35	LIVB 401 410	pacientes
#33	AnnotatorNotes T35	C0030705; Patients; Patient or Disabled Group
T36	LIVB 511 520	pacientes
#34	AnnotatorNotes T36	C0030705; Patients; Patient or Disabled Group
T37	Dose 579 586	5 mg/kg
T38	Route 587 591	i.v.
#35	AnnotatorNotes T38	C1522726; Intravenous Route of Drug Administration; Functional Concept
T39	Duration 595 615	las semanas 0, 2 y 6
T40	LIVB 626 635	pacientes
#36	AnnotatorNotes T40	C0030705; Patients; Patient or Disabled Group
T42	Dose 793 800	3 dosis
T43	Date 936 949	a largo plazo
T44	Dose 994 1001	5 mg/kg
T45	Route 1002 1006	i.v.
#37	AnnotatorNotes T45	C1522726; Intravenous Route of Drug Administration; Functional Concept
T46	Frequency 1008 1022	cada 8 semanas
T47	Duration 1032 1040	1-2 años
T48	LIVB 1095 1104	pacientes
#38	AnnotatorNotes T48	C0030705; Patients; Patient or Disabled Group
T49	LIVB 1219 1228	pacientes
#39	AnnotatorNotes T49	C0030705; Patients; Patient or Disabled Group
T52	LIVB 1445 1453	paciente
#40	AnnotatorNotes T52	C0030705; Patients; Patient or Disabled Group
T53	Duration 1523 1538	36 ± 12 semanas
T54	Duration 1546 1550	8-72
T56	Date 1820 1833	a largo plazo
T57	LIVB 1873 1882	pacientes
#41	AnnotatorNotes T57	C0030705; Patients; Patient or Disabled Group
T41	Duration 812 828	semanas 0, 2 y 6
T58	Dose 962 977	dosis repetidas
T50	Dose 1461 1468	4,4 ± 2
T51	Dose 1476 1479	1-9
T55	DISO 709 718	recayeron
#42	AnnotatorNotes T55	C2825055; Recurrence (disease attribute); Pathologic Function
A1	Status T8 History_of
T59	Observation 643 655	respondieron
A2	Assertion T59 Negated
T60	Neg_cue 640 642	no
#43	AnnotatorNotes T59	C1319171; Medication response; Finding
R1	Negation Arg1:T60 Arg2:T59	
R2	Experiences Arg1:T40 Arg2:T59	
T61	Observation 736 746	respondido
#44	AnnotatorNotes T61	C1319171; Medication response; Finding
R3	Experiences Arg1:T40 Arg2:T61	
R4	After Arg1:T55 Arg2:T61	
R5	Experiences Arg1:T40 Arg2:T55	
T62	CONC 668 673	ciclo
R6	After Arg1:T59 Arg2:T62	
T63	Quantifier_or_Qualifier 674 681	inicial
R7	Has_Quantifier_or_Qualifier Arg1:T62 Arg2:T63	
T64	Neg_cue 1574 1576	no
T65	CONC 1577 1587	aumentaron
A3	Assertion T65 Negated
#45	AnnotatorNotes T65	C0442805; Increase; Functional Concept
R8	Negation Arg1:T64 Arg2:T65	
T66	Observation 1245 1258	respondedores
#46	AnnotatorNotes T66	C0919876; Therapy responder; Finding
A4	Assertion T66 Negated
T67	Neg_cue 1242 1244	no
R9	Negation Arg1:T67 Arg2:T66	
R10	Used_for Arg1:T27 Arg2:T2	
R13	Overlap Arg1:T5 Arg2:T32	
R14	Used_for Arg1:T4 Arg2:T5	
R16	Overlap Arg1:T9 Arg2:T33	
R17	Experiences Arg1:T34 Arg2:T6	
R18	Used_for Arg1:T10 Arg2:T6	
R19	Experiences Arg1:T35 Arg2:T6	
R20	Experiences Arg1:T35 Arg2:T12	
T68	Quantifier_or_Qualifier 411 423	consecutivos
#47	AnnotatorNotes T68	C1707491; Consecutive; Qualitative Concept
R21	Has_Quantifier_or_Qualifier Arg1:T35 Arg2:T68	
T69	Quantifier_or_Qualifier 441 447	activa
#48	AnnotatorNotes T69	C0679217; Active State; Idea or Concept
R22	Has_Quantifier_or_Qualifier Arg1:T12 Arg2:T69	
R23	Experiences Arg1:T35 Arg2:T8	
T70	Observation 471 491	fallado tratamientos
R26	Before Arg1:T8 Arg2:T70	
R27	Experiences Arg1:T34 Arg2:T70	
R28	Experiences Arg1:T35 Arg2:T70	
#49	AnnotatorNotes T70	C0162643; treatment failure; Finding
R29	Experiences Arg1:T34 Arg2:T12	
R30	Experiences Arg1:T34 Arg2:T8	
R31	Experiences Arg1:T36 Arg2:T13	
R32	Experiences Arg1:T36 Arg2:T28	
R33	Has_Dose_or_Strength Arg1:T28 Arg2:T37	
R34	Has_Route_or_Mode Arg1:T28 Arg2:T38	
R35	Has_Duration_or_Interval Arg1:T28 Arg2:T39	
R36	Experiences Arg1:T40 Arg2:T11	
R38	Before Arg1:T59 Arg2:T11	
R39	Has_Dose_or_Strength Arg1:T11 Arg2:T42	
R40	Has_Duration_or_Interval Arg1:T11 Arg2:T41	
T71	Observation 1105 1130	respondieron parcialmente
R41	Experiences Arg1:T48 Arg2:T71	
T72	Observation 844 856	respondieron
R42	Overlap Arg1:T72 Arg2:T15	
R43	Before Arg1:T72 Arg2:T14	
R44	Overlap Arg1:T14 Arg2:T43	
R45	Has_Dose_or_Strength Arg1:T14 Arg2:T58	
R46	Has_Dose_or_Strength Arg1:T29 Arg2:T44	
R47	Has_Route_or_Mode Arg1:T29 Arg2:T45	
R48	Has_Frequency Arg1:T29 Arg2:T46	
R49	Has_Duration_or_Interval Arg1:T29 Arg2:T47	
R50	Has_Duration_or_Interval Arg1:T14 Arg2:T47	
R51	Before Arg1:T72 Arg2:T29	
R52	Experiences Arg1:T48 Arg2:T17	
R53	Overlap Arg1:T17 Arg2:T71	
#50	AnnotatorNotes T71	C1521726; partial response; Finding
T73	Observation 1272 1290	respuesta completa
#51	AnnotatorNotes T73	C0677874; In complete remission; Finding
R54	Experiences Arg1:T49 Arg2:T66	
R56	Before Arg1:T66 Arg2:T16	
R57	Overlap Arg1:T16 Arg2:T73	
R58	Experiences Arg1:T49 Arg2:T73	
T74	Observation 1318 1330	recidivantes
#52	AnnotatorNotes T74	C0679254; Disease recurrence; Finding
R55	Experiences Arg1:T49 Arg2:T74	
R59	Before Arg1:T16 Arg2:T74	
T75	Observation 1393 1402	respuesta
R60	Overlap Arg1:T19 Arg2:T75	
T76	CONC 1435 1440	dosis
#53	AnnotatorNotes T76	C0178602; Dosage; Quantitative Concept
R61	Has_Dose_or_Strength Arg1:T76 Arg2:T50	
R62	Has_Dose_or_Strength Arg1:T76 Arg2:T51	
R63	Has_Duration_or_Interval Arg1:T20 Arg2:T53	
R64	Used_for Arg1:T76 Arg2:T20	
R65	Has_Duration_or_Interval Arg1:T20 Arg2:T54	
R66	Experiences Arg1:T52 Arg2:T20	
R67	Causes Arg1:T26 Arg2:T21	
R68	Causes Arg1:T22 Arg2:T21	
R69	Used_for Arg1:T23 Arg2:T30	
R70	Used_for Arg1:T23 Arg2:T18	
R71	Used_for Arg1:T23 Arg2:T24	
R72	Overlap Arg1:T24 Arg2:T56	
T77	Observation 1855 1869	bien toleradas
R73	Experiences Arg1:T57 Arg2:T25	
R74	Experiences Arg1:T57 Arg2:T77	
R75	Experiences Arg1:T57 Arg2:T30	
R76	Experiences Arg1:T57 Arg2:T18	
R77	Experiences Arg1:T57 Arg2:T24	
R78	Overlap Arg1:T30 Arg2:T77	
T78	Observation 1142 1160	respuesta completa
R80	Experiences Arg1:T48 Arg2:T78	
R81	Overlap Arg1:T17 Arg2:T78	
#54	AnnotatorNotes T78	C0677874; In complete remission; Finding
T79	Quantifier_or_Qualifier 1403 1409	global
#55	AnnotatorNotes T79	C2348867; Global; Qualitative Concept
R82	Has_Quantifier_or_Qualifier Arg1:T75 Arg2:T79	
R85	Overlap Arg1:T24 Arg2:T77	
R86	Overlap Arg1:T18 Arg2:T77	
#57	AnnotatorNotes T77	C5684674; patient tolerated procedure well; Finding
#58	AnnotatorNotes T75	C4055223; Clinical Response; Finding
T81	Quantifier_or_Qualifier 1588 1606	significativamente
A5	Assertion T81 Negated
#59	AnnotatorNotes T81	C0750502; Significant; Idea or Concept
R87	Has_Quantifier_or_Qualifier Arg1:T65 Arg2:T81	
R88	Negation Arg1:T64 Arg2:T81	
R11	Before Arg1:T70 Arg2:T6	
#60	AnnotatorNotes T63	C0205265; Initially; Temporal Concept
#61	AnnotatorNotes T72	C1319171; Medication response; Finding
#56	AnnotatorNotes T56	C0443252; Long-term; Temporal Concept
#62	AnnotatorNotes T33	C0443252; Long-term; Temporal Concept
#63	AnnotatorNotes T43	C0443252; Long-term; Temporal Concept
#64	AnnotatorNotes T32	C0443303; short-term; Temporal Concept
A6	Experiencer T52 Patient
A7	Experiencer T35 Patient
A8	Experiencer T34 Patient
A9	Experiencer T36 Patient
A10	Experiencer T40 Patient
A11	Experiencer T48 Patient
A12	Experiencer T49 Patient
A13	Experiencer T57 Patient
